Q4 2025 MiMedx Group Inc Earnings Call Transcript
Key Points
- MiMedx Group Inc (MDXG) achieved record highs for revenue and adjusted EBITDA in 2025, with a net cash balance of nearly $150 million at year-end.
- The Surgical business grew by 20% for the full year 2025, benefiting from strategic investments and expected to maintain momentum into the new year.
- Fourth quarter year-over-year net sales growth was 27%, with both Wound and Surgical segments growing at or above 25%.
- The company ended the year with $148 million in net cash, a sequential increase of $24 million in the quarter.
- MiMedx Group Inc (MDXG) announced a share repurchase program, authorizing management to buy back up to $100 million in stock over the next two years.
- The Wound Care market is experiencing disruption due to the recalibration of the Medicare reimbursement rate for skin substitutes, effective January 1.
- There is significant market noise and adjustments as providers adapt to new reimbursement frameworks, with some products being dumped at very low prices.
- The company anticipates a sequential build in revenue throughout 2026, with the first couple of quarters expected to be noisy and challenging.
- MiMedx Group Inc (MDXG) expects its gross margin to decrease to the mid- to upper 70s in 2026 due to lower wound ASPs and lower margins from new products.
- The company is facing increased audits and clawbacks, causing nervousness among providers and impacting market stability.
Good afternoon, and thank you for standing by. Welcome to the MiMedx fourth quarter and full year 2025 operating and financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Matt Notarianni, Head of Investor Relations from MiMedx. Thank you, Matt. You may begin.
Thank you, operator, and good afternoon, everyone. Welcome to the MiMedx fourth quarter and full year 2025 operating and financial results conference call. With me on today's call are Chief Officer, Joe Capper; and Chief Financial Officer, Doug Rice. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at mimedx.com.
Joe will kick us off with some opening remarks and a summary of our operating highlights as well as a discussion of the market environment and our financial goals. Next, Doug will provide a review of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
